GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Glecaprevir/pibrentasvir (Mavyret), adult oral HCV treatment

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Mavyret - labeled renal guidance

Product / population
Glecaprevir/pibrentasvir (Mavyret), adult oral HCV treatment
Renal method
Clinical renal category or population named in the cited section
Source revision
DailyMed SPL version 201, effective 2025-06-25; posted Aug 07, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Mavyret - product and source limitations

Treatment duration depends on HCV and transplant history. Check hepatic eligibility and interactions separately.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Mavyret - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Glecaprevir/pibrentasvir (Mavyret), adult oral HCV treatment

Renal method: Clinical renal category or population named in the cited section
Source date: DailyMed SPL version 201, effective 2025-06-25; posted Aug 07, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8, renal impairment

Renal impairment requires no dose adjustment, including in dialysis patients. Treatment duration depends on HCV and transplant history. Check hepatic eligibility and interactions separately.

RDM73-mavyret-official-1 · Source locator: Renal guidance: 8, renal impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf99777-0401-9095-8645-16c6e907fcc0
Retrieved
2026-11-07
Renal-function method
Clinical renal category or population named in the cited section
Source date/version
DailyMed SPL version 201, effective 2025-06-25; posted Aug 07, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
aefcf3b7792112fe43002de03ccb8792c51bfb0583491eb09f5e95ec8c551055

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=glecaprevir-pibrentasvir-mavyret&s1=RDM73-mavyret-official&h1=7da9257a041017ee8faa55a7aaf3d1a4d8623180ed27d75d0d9f9a8e405abf0c

Top